Merck Gets Positive EU Opinion to Expand ENFLONSIA Use for Young Children

By Reuters News

- Merck & Co Inc MRK.N:

  • MERCK RECEIVES POSITIVE EU CHMP OPINION TO EXPAND MARKETING AUTHORIZATION FOR ENFLONSIA® (CLESROVIMAB) TO INCLUDE CHILDREN UP TO 24 MONTHS OF AGE WHO REMAIN VULNERABLE TO SEVERE RSV DISEASE THROUGH THEIR SECOND RSV SEASON

  • MERCK: FINAL EU COMMISSION DECISION ON ENFLONSIA EXPANSION EXPECTED WITHIN TWO MONTHS

Further company coverage: MRK.N

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk